EA200601796A1 - Pyrimidine derivatives for the treatment of anomalous cell growth - Google Patents
Pyrimidine derivatives for the treatment of anomalous cell growthInfo
- Publication number
- EA200601796A1 EA200601796A1 EA200601796A EA200601796A EA200601796A1 EA 200601796 A1 EA200601796 A1 EA 200601796A1 EA 200601796 A EA200601796 A EA 200601796A EA 200601796 A EA200601796 A EA 200601796A EA 200601796 A1 EA200601796 A1 EA 200601796A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- treatment
- cell growth
- pyrimidine derivatives
- anomalous cell
- mammals
- Prior art date
Links
- 230000010261 cell growth Effects 0.000 title abstract 3
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title abstract 2
- 150000003230 pyrimidines Chemical class 0.000 title abstract 2
- 230000002547 anomalous effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 230000002159 abnormal effect Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Настоящее изобретение относится к соединению формулы (I), где R-Rтакие, как они определены в данном описании изобретения. Такие новые пиримидиновые производные полезны в лечении аномального клеточного роста, например рака, у млекопитающих. Данное изобретение также относится к способу применения таких соединений в лечении аномального клеточного роста у млекопитающих, в особенности людей, и к фармацевтическим композициям, содержащим такие соединения.The present invention relates to a compound of formula (I), wherein R-R are as defined herein. Such novel pyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. The present invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57131204P | 2004-05-14 | 2004-05-14 | |
| PCT/IB2005/001201 WO2005111023A1 (en) | 2004-05-14 | 2005-05-02 | Pyrimidine derivatives for the treatment of abnormal cell growth |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA200601796A1 true EA200601796A1 (en) | 2007-04-27 |
Family
ID=34966230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200601796A EA200601796A1 (en) | 2004-05-14 | 2005-05-02 | Pyrimidine derivatives for the treatment of anomalous cell growth |
Country Status (27)
| Country | Link |
|---|---|
| EP (1) | EP1751143A1 (en) |
| JP (1) | JP4099212B2 (en) |
| KR (1) | KR100886990B1 (en) |
| CN (2) | CN102127058A (en) |
| AP (1) | AP2241A (en) |
| AR (1) | AR049097A1 (en) |
| AU (2) | AU2005243397A1 (en) |
| BR (1) | BRPI0511138A (en) |
| CA (1) | CA2566707A1 (en) |
| CR (1) | CR8749A (en) |
| EA (1) | EA200601796A1 (en) |
| EC (1) | ECSP066997A (en) |
| GE (1) | GEP20104875B (en) |
| GT (1) | GT200500113A (en) |
| IL (1) | IL178828A0 (en) |
| MA (1) | MA28583B1 (en) |
| MX (1) | MXPA06011890A (en) |
| NL (2) | NL1029045C2 (en) |
| NO (1) | NO20064576L (en) |
| NZ (1) | NZ550448A (en) |
| PA (1) | PA8632601A1 (en) |
| PE (1) | PE20060240A1 (en) |
| TN (1) | TNSN06370A1 (en) |
| TW (1) | TWI303635B (en) |
| UY (1) | UY28894A1 (en) |
| WO (1) | WO2005111023A1 (en) |
| ZA (1) | ZA200608394B (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2566531A1 (en) * | 2004-05-18 | 2005-12-15 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
| US20070032514A1 (en) * | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
| AP2008004488A0 (en) * | 2005-12-21 | 2008-06-30 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| WO2008129380A1 (en) * | 2007-04-18 | 2008-10-30 | Pfizer Products Inc. | Sulfonyl amide derivatives for the treatment of abnormal cell growth |
| WO2009012421A1 (en) * | 2007-07-17 | 2009-01-22 | Rigel Pharmaceuticals, Inc. | Cyclic amine substituted pyrimidinediamines as pkc inhibitors |
| EP2231620A1 (en) * | 2007-12-03 | 2010-09-29 | Boehringer Ingelheim International GmbH | Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation |
| PL2300013T5 (en) * | 2008-05-21 | 2025-04-28 | Takeda Pharmaceutical Company Limited | Phosphorous derivatives as kinase inhibitors |
| US8410126B2 (en) * | 2009-05-29 | 2013-04-02 | Boehringer Ingelheim International Gmbh | Pyrimidine inhibitors of PKTK2 |
| US8729265B2 (en) | 2009-08-14 | 2014-05-20 | Boehringer Ingelheim International Gmbh | Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives |
| US8933227B2 (en) | 2009-08-14 | 2015-01-13 | Boehringer Ingelheim International Gmbh | Selective synthesis of functionalized pyrimidines |
| US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
| JPWO2014174745A1 (en) * | 2013-04-26 | 2017-02-23 | 国立大学法人京都大学 | Eg5 inhibitor |
| CN109608444B (en) * | 2018-11-27 | 2022-02-11 | 中国药科大学 | ERK inhibitor containing isoindolinone and preparation method and use thereof |
| CN111732548B (en) * | 2020-06-11 | 2022-06-17 | 浙江大学 | N2-carbamyl aromatic ring-2-aminopyrimidine derivatives and medical application thereof |
| WO2024140671A1 (en) * | 2022-12-29 | 2024-07-04 | 南京昕瑞再生医药科技有限公司 | Fused tricyclic derivative, pharmaceutical composition comprising same, and use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9721437D0 (en) * | 1997-10-10 | 1997-12-10 | Glaxo Group Ltd | Heteroaromatic compounds and their use in medicine |
| AR042586A1 (en) | 2001-02-15 | 2005-06-29 | Sugen Inc | 3- (4-AMIDOPIRROL-2-ILMETILIDEN) -2-INDOLINONE AS INHIBITORS OF PROTEIN KINASE; YOUR PHARMACEUTICAL COMPOSITIONS; A METHOD FOR THE MODULATION OF THE CATALYTIC ACTIVITY OF PROTEINQUINASE; A METHOD TO TREAT OR PREVENT AN AFFECTION RELATED TO PROTEINQUINASE |
| WO2003030909A1 (en) * | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| WO2004056807A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
| UA80767C2 (en) * | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
-
2005
- 2005-05-02 WO PCT/IB2005/001201 patent/WO2005111023A1/en not_active Ceased
- 2005-05-02 NZ NZ550448A patent/NZ550448A/en not_active IP Right Cessation
- 2005-05-02 CN CN2011100212904A patent/CN102127058A/en active Pending
- 2005-05-02 AU AU2005243397A patent/AU2005243397A1/en not_active Abandoned
- 2005-05-02 CN CNA2005800155302A patent/CN1953974A/en active Pending
- 2005-05-02 MX MXPA06011890A patent/MXPA06011890A/en unknown
- 2005-05-02 BR BRPI0511138-2A patent/BRPI0511138A/en not_active IP Right Cessation
- 2005-05-02 EA EA200601796A patent/EA200601796A1/en unknown
- 2005-05-02 KR KR1020067023767A patent/KR100886990B1/en not_active Expired - Lifetime
- 2005-05-02 GE GEAP20059703A patent/GEP20104875B/en unknown
- 2005-05-02 JP JP2007512557A patent/JP4099212B2/en not_active Expired - Lifetime
- 2005-05-02 EP EP05732043A patent/EP1751143A1/en not_active Withdrawn
- 2005-05-02 CA CA002566707A patent/CA2566707A1/en not_active Abandoned
- 2005-05-02 AP AP2006003790A patent/AP2241A/en active
- 2005-05-11 TW TW094115237A patent/TWI303635B/en not_active IP Right Cessation
- 2005-05-11 PA PA20058632601A patent/PA8632601A1/en unknown
- 2005-05-12 UY UY28894A patent/UY28894A1/en not_active Application Discontinuation
- 2005-05-12 PE PE2005000534A patent/PE20060240A1/en not_active Application Discontinuation
- 2005-05-13 NL NL1029045A patent/NL1029045C2/en not_active IP Right Cessation
- 2005-05-13 GT GT200500113A patent/GT200500113A/en unknown
- 2005-05-13 AR ARP050101969A patent/AR049097A1/en not_active Application Discontinuation
-
2006
- 2006-05-19 NL NL1031845A patent/NL1031845C2/en not_active IP Right Cessation
- 2006-10-06 ZA ZA200608394A patent/ZA200608394B/en unknown
- 2006-10-09 NO NO20064576A patent/NO20064576L/en not_active Application Discontinuation
- 2006-10-23 IL IL178828A patent/IL178828A0/en unknown
- 2006-11-13 CR CR8749A patent/CR8749A/en not_active Application Discontinuation
- 2006-11-13 TN TNP2006000370A patent/TNSN06370A1/en unknown
- 2006-11-13 EC EC2006006997A patent/ECSP066997A/en unknown
- 2006-11-14 MA MA29452A patent/MA28583B1/en unknown
-
2009
- 2009-11-13 AU AU2009238255A patent/AU2009238255A1/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200801287A1 (en) | Pyrimidine derivatives for the treatment of anomalous cell growth | |
| TW200607801A (en) | Pyrimidine derivatives for the treatment of abnormal cell growth | |
| TNSN06074A1 (en) | Pyrimidine derivatives for the treatment of abnormal cell growth | |
| TW200612949A (en) | Pyrimidine derivatives for the treatment of abnormal cell growth | |
| EA200901250A1 (en) | SULPHONYLAMID DERIVATIVES FOR THE TREATMENT OF ANOMALOUS GROWTH OF CELLS | |
| EA200971104A1 (en) | Derivatives of benzimidazole | |
| MXPA06013164A (en) | Pyrimidines derivatives for the treatment of abnormal cell growth. | |
| EA200701808A1 (en) | Derivatives of tetrahydroindolone and tetrahydroindazole | |
| EA200800172A1 (en) | 2,4-DIAMINOPYRIMIDINES AS AURORA INHIBITORS | |
| NO20071642L (en) | N-Benzenesulfonyl-substituted anilino-pyrimidine analogs | |
| EA200601796A1 (en) | Pyrimidine derivatives for the treatment of anomalous cell growth | |
| MXPA05012025A (en) | Imidazo and thiazolopyridines as jak3 kinase inhibitors. | |
| EA200800047A1 (en) | DERIVATIVES OF PYRIMIDINE | |
| NO20085176L (en) | Phenyl substituted heteroaryl derivatives and use as anti-tumor agents | |
| EA200500203A1 (en) | NEW METHOD OF SYNTHESIS AND NEW CRYSTAL FORM OF AGOMELATIN AND PHARMACEUTICAL COMPOSITIONS THAT HERE CONTAINS | |
| MXPA05010440A (en) | Isoquinoline-5-sulfonic acid amides as inhibitors of akt (protein kinase b). | |
| EA200601065A1 (en) | DERIVATIVES OF IMIDAZOL, METHODS OF THEIR PRODUCTION AND APPLICATION | |
| EA200801608A1 (en) | DERIVATIVES OF BENZIMIDAZOLONIC CARBONIC ACID | |
| ES2368594T3 (en) | SUBSTITUTED DERIVATIVES OF CYCLOHEXILMETILO. | |
| EA200701930A1 (en) | Derivatives of pyrimidine for the treatment of hyperproliferative disorders | |
| EA200702375A1 (en) | UREA DERIVATIVES, METHODS FOR THEIR RECEPTION AND APPLICATION | |
| ATE543803T1 (en) | 3-Ä2-(3-AZYLAMINO-2-OXO-2H-PYRIDINE-1-YL)ACETYLAMINOÜ-4-OXOPENTANIC ACID DERIVATIVES AND THEIR USE AS CASPASE INHIBITORS | |
| WO2007076087A3 (en) | 3-aryl-substituted quinazolones, and uses thereof | |
| TW200505869A (en) | Thiophenylaminoimidazolines | |
| MY153733A (en) | Novel quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same |